Gastroenterology & Hepatology Clinical Trials

Statistical methods in gastroenterology & hepatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All gastroenterology & hepatology trials

642 results

• KAMELEONIndependent statistical analysis of A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 20NCT02999672
• Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases: Complete Statistical AnalysisIndependent statistical analysis of Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01944930).Phase 1Results postedn = 23NCT01944930
• Laparoscopic Versus Open Appendectomy? Let the Patient Decide: Complete Statistical AnalysisIndependent statistical analysis of Laparoscopic Versus Open Appendectomy? Let the Patient Decide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01738750).Phase NAResults postedn = 100NCT01738750
• Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ): Complete Statistical AnalysisIndependent statistical analysis of Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 13NCT01395537
• Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 10NCT02301936
• Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 40NCT02219685
• LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 12NCT02985125
• LETISIndependent statistical analysis of Assessing the Effect of Lettuce on Intestinal Water Content Through Magnetic Resonance Imaging of the Small Bowel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 18NCT02939716
• Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation: Complete Statistical AnalysisIndependent statistical analysis of Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 35NCT04110145
• Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial: Complete Statistical AnalysisIndependent statistical analysis of Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial:…Phase 2Results postedn = 8NCT03690921
• LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 32NCT02631772
• Liver Fibrosis Evaluation Using Ultrasound Shear Wave Imaging: Complete Statistical AnalysisIndependent statistical analysis of Liver Fibrosis Evaluation Using Ultrasound Shear Wave Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03637959).Phase NAResults postedn = 270NCT03637959
• Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg): Complete Statistical AnalysisIndependent statistical analysis of Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen…Phase 4Results postedn = 36NCT00240539
• Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 157NCT01519661
• Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer: Complete Statistical AnalysisIndependent statistical analysis of Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 395NCT00595517
• Long-Term Immune Persistence of GSK Biologicals’ Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule: Complete Statistical AnalysisIndependent statistical analysis of Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 51NCT00289718
• Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals’ Hepatitis B Vaccine (HBV), Engerix-B: Complete Statistical AnalysisIndependent statistical analysis of Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 4Results postedn = 106NCT02901951
• Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Complete Statistical AnalysisIndependent statistical analysis of Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 3,502NCT02099708
• Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates: Complete Statistical AnalysisIndependent statistical analysis of Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 136NCT01050660
• Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor: Complete Statistical AnalysisIndependent statistical analysis of Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 170NCT05782816
• Low-Level Laser Therapy for Prevention of Oral Mucositis: Complete Statistical AnalysisIndependent statistical analysis of Low-Level Laser Therapy for Prevention of Oral Mucositis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02682992).Phase NAResults postedn = 47NCT02682992
• Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation: Complete Statistical AnalysisIndependent statistical analysis of Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 64NCT00662363
• LUCENT 2Independent statistical analysis of A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 1,328NCT03524092
• MADIndependent statistical analysis of Magnetic Anastomosis Device Relief of Malignant Gastric Outlet Obstruction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00487552).Phase NAResults postedn = 18NCT00487552
• MAGE-A4ᶜ¹º³²T for Multi-Tumor: Complete Statistical AnalysisIndependent statistical analysis of MAGE-A4ᶜ¹º³²T for Multi-Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03132922).Phase 1Results postedn = 71NCT03132922
• MAGELLAN-3Independent statistical analysis of Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in…Phase 3Results postedn = 33NCT02939989
• MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients): Complete Statistical AnalysisIndependent statistical analysis of MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 43NCT04724291
• MasterKey-01Independent statistical analysis of A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1Results postedn = 91NCT04209465
• MAVERICIndependent statistical analysis of Maraviroc Efficacy for Hepatitis C: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02881762).Phase 4Results postedn = 10NCT02881762
• McCAVEIndependent statistical analysis of A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer: primary endpoint results, effect estimate with…Phase 2Results postedn = 197NCT02141295
• MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery: Complete Statistical AnalysisIndependent statistical analysis of MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 27NCT00112580
• MDX1106-01Independent statistical analysis of A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 39NCT00441337
• MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC): Complete Statistical AnalysisIndependent statistical analysis of MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 16NCT01085331
• Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC): Complete Statistical AnalysisIndependent statistical analysis of Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 228NCT02522767
• METRASIndependent statistical analysis of Metabolites of Tramadol in the Postoperative Surgical Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04004481).Phase NAResults postedn = 50NCT04004481
• MgPOEMIndependent statistical analysis of Magnesium for Peroral Endoscopic Myotomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04638881).Phase 2Results postedn = 92NCT04638881
• Minimally Invasive Surgery (MIS) Database for the Purpose of Research: Complete Statistical AnalysisIndependent statistical analysis of Minimally Invasive Surgery (MIS) Database for the Purpose of Research: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00535990).Phase NAResults postedn = 250NCT00535990
• MIRNAIndependent statistical analysis of Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04321031).Phase 2Results postedn = 256NCT04321031
• Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment: Complete Statistical AnalysisIndependent statistical analysis of Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02806869).Phase NAResults postedn = 48NCT02806869
• Molecular-Guided Therapy for Childhood Cancer: Complete Statistical AnalysisIndependent statistical analysis of Molecular-Guided Therapy for Childhood Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02162732).Phase NAResults postedn = 186NCT02162732
• Monitoring of Symptoms and Cognitive Function Using Telehealth: Complete Statistical AnalysisIndependent statistical analysis of Monitoring of Symptoms and Cognitive Function Using Telehealth: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03184701).Phase NAResults postedn = 45NCT03184701
• MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01180634).Phase 3Results postedn = 330NCT01180634
• MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED): Complete Statistical AnalysisIndependent statistical analysis of MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 17NCT00857311
• MUCINIndependent statistical analysis of Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 140NCT01769248
• Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.: Complete Statistical AnalysisIndependent statistical analysis of Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only…Phase 3Results postedn = 515NCT02273141
• Multidisciplinary Support Program in Chronic Hepatitis C: Complete Statistical AnalysisIndependent statistical analysis of Multidisciplinary Support Program in Chronic Hepatitis C: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01850745).Phase NAResults postedn = 447NCT01850745
• MYCureIndependent statistical analysis of Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1/2Results postedn = 22NCT04808362
• N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure: Complete Statistical AnalysisIndependent statistical analysis of N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00248625).Phase 3Results postedn = 184NCT00248625
• Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA: Complete Statistical AnalysisIndependent statistical analysis of Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01893801).Phase 1/2Results postedn = 25NCT01893801
• Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: primary endpoint results, effect estimate with…Phase 2Results postedn = 20NCT02427841

← All therapeutic areas